Leukocyte response to thymoglobulin or Atgam for induction immunosuppression in a randomized, double-blind clinical trial in renal transplant recipients
- 1 May 1999
- journal article
- clinical trial
- Published by Elsevier in Transplantation Proceedings
- Vol. 31 (3) , 16S-18S
- https://doi.org/10.1016/s0041-1345(99)00096-2
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- RESULTS OF THE DOUBLE-BLIND, RANDOMIZED, MULTICENTER, PHASE III CLINICAL TRIAL OF THYMOGLOBULIN VERSUS ATGAM IN THE TREATMENT OF ACUTE GRAFT REJECTION EPISODES AFTER RENAL TRANSPLANTATION1,2Transplantation, 1998
- A RANDOMIZED CLINICAL TRIAL OF INDUCTION THERAPY WITH OKT3 IN KIDNEY TRANSPLANTATIONTransplantation, 1993
- ANALYSES OF THE UNOS SCIENTIFIC RENAL TRANSPLANT REGISTRY AT THREE YEARS—EARLY EVENTS AFFECTING TRANSPLANT SUCCESS1–3Transplantation, 1992
- SYMPTOMATIC CYTOMEGALOVIRUS DISEASE IN THE CYTOMEGALOVIRUS ANTIBODY SEROPOSITIVE RENAL TRANSPLANT RECIPIENT TREATED WITH OKT31,2Transplantation, 1992
- Increased Incidence of Lymphoproliferative Disorder after Immunosuppression with the Monoclonal Antibody OKT3 in Cardiac-Transplant RecipientsNew England Journal of Medicine, 1990